Video | Business Headlines | Internet | Science | Scientific Ethics | Technology | Search


Steroids Help Treat Critically Ill COVID-19 Patients – Expert Reaction

A review of seven clinical trials finds corticosteroids improve the chance of survival for COVID-19 patients.

The research pooled data from more than 1,700 patients from around the world, including a trial run in New Zealand. It is authored by the World Health Organization's REACT working group, which includes a New Zealand scientist.

The SMC asked experts to comment on the study.

Dr Michael Maze, Respiratory and Infectious Disease Physician, University of Otago, comments:

"This publication provides valuable information for doctors treating COVID-19 patients. The study combines the information from almost all the relevant clinical trials that have been investigating whether corticosteroid drugs help people who are critically unwell with COVID-19 survive. They found that across the studies corticosteroids reduced the chance of death by around one third.

"This is important, as it is a readily available treatment that can be used in New Zealand from today. We need to remember that it is not a cure, and that even with corticosteroids, around 1 in every three patients enrolled still died. We also need to remember that the study is only of patients who are critically unwell with COVID-19 – the patients who are needing help with breathing on a ventilator, or who are otherwise extremely unwell.

"The existing information from studies including patients who are sick enough to be in hospital on oxygen, but not on a ventilator, have shown a smaller benefit, and we don’t have data to suggest that corticosteroids help patients with COVID-19 who are well enough to be at home."

No conflict of interest declared.

Christopher Gale, Clinical Lecturer, Department of Psychological Medicine, University of Otago Medical School, Dunedin, comments:

"This paper will be read with interest by intensive care physicians and general physicians, and it could mean that a corticosteroid becomes part of the management protocol for acute respiratory distress associated with COVID-19. However, the results are skewed by one large study, and it would be hard to confidently choose one corticosteroid over another, or low dose over high dose, because, as the authors note, the comparisons were not able to be precisely estimated.

"Data from seven trials was pooled with a total of 1703 critically ill patients from 13 countries including New Zealand. One trial was excluded because it was published after the cut off date for the protocol, and one other trial was still recruiting patients at the time of meta analysis. One study from Denmark contributed 1000 patients to the population.

"The meta analysis suggests that the use of corticosteroid did make a significant reduction in the 28 day mortality rate. This seemed to be more apparent if one considered only those who had mechanical ventilation: 30% of those patients receiving steroids died compared with 40% receiving usual care in the whole group. That is a difference of 10% which implies you would need to treat 10 people to save one life. Among those who had mechanical ventilation 30% of those receiving corticosteroids died compared with 38% for placebo. That is a small but significant absolute difference of 8% which implies you would need to treat 12.5 people to save an extra life.

"The patients in this group are extremely sick. Corticosteroids make a small difference, but in people with respiratory distress small differences matter. The number of adverse effects was lower among those treated with corticosteroids.

"Three of the studies used high doses of corticosteroids, four used lower doses. All studies allowed usual care for patients in addition: Four studies recorded the use of antivirals, four different studies recorded the number of participants with hydroxychloroquine, four papers recorded the use of Azathioprine, and one paper the use of convalescent plasma. This variation in medications across studies, with people this sick, is not unusual, but is a limitation on the analysis.

"There were no significant differences noted in the response rate by age, gender, or rapidity or number of days the patient had symptoms for."

Disclaimer: I have worked on Cochrane protocols and meta analysis and on reviews of meta analysis for BMJ Clinical Evidence and BMJ Best Practice. I am not an intensivist: I am reviewing the paper from an Evidence based Medicine position.

Professor Kurt Krause, Infectious Diseases Physician; Professor of Biochemistry, University of Otago, comments:

"This meta-analysis centres on the effect of corticosteroid administration to critically ill patients with COVID-19. To complete this analysis they considered 7 randomised controlled trials involving 1703 patients. 1025 of these patients received either placebo or usual treatment while 678 patients were randomised to receive either dexamethasone, hydrocortisone or methylprednisolone. The primary outcome reported was all cause mortality at 28 days following randomisation.

"The main overall finding was a significant reduction in mortality in severely ill patients receiving steroids (Odds ratio 0.66). A positive benefit was found in patients who received dexamethasone and hydrocortisone but not in those who received methylprednisolone, although patient numbers for the latter group were very small. There was no measurable benefit found in administering corticosteroids to patients who were on medication to support their blood pressure. This group of patients would be among the most critically ill, and high mortality in this group would be expected.

"Overall this study in mostly in line with data from the RECOVERY trial released earlier this year showing a significant benefit from the use of dexamethasone in critically ill COVID-19 patients. This is not surprising especially given that the RECOVERY dataset was included in this meta-analysis. Continued use of corticosteroids in critically ill patients with COVID-19 would be expected to continue following this study. The results for patients requiring vasoactive medications will need to be followed up on. The results with methylprednisolone involve a small number of patients and are not statistically significant."

No conflict of interest declared.

© Scoop Media

Business Headlines | Sci-Tech Headlines


Auckland Transport: Successful Bridge Repair Opens Two Additional Lanes To Traffic

The opening of two additional lanes on the Auckland Harbour Bridge this morning will help relieve some motorway congestion for motorists heading home to the North Shore tonight. More>>


Statistics New Zealand: COVID-19 Sees Record 12.2 Percent Fall In New Zealand’s Economy

Gross domestic product (GDP) fell by 12.2 percent in the June 2020 quarter, the largest quarterly fall recorded since the current series began in 1987, as the COVID-19 restrictions in place through the quarter impacted economic activity, Stats NZ said ... More>>


Climate: Scientists Release ‘Blueprint’ To Save Critical Ecosystems And Stabilize The Earth’s Climate

A group of scientists and experts produced the first comprehensive global-scale analysis of terrestrial areas essential for biodiversity and climate resilience, totaling 50.4% of the Earth's land. The report was published in Science Advances ... More>>


MPI: Independent Review Launched Into Assurances For Safe Transport Of Livestock By Sea

The Ministry for Primary Industries (MPI) has launched an independent review of the assurances it receives for the safe transport of livestock by sea. MPI Director-General Ray Smith says Mike Heron QC has been appointed to lead the review, which is expected ... More>>


Computers: New Zealand PC Market Grows Nearly 40% Due To Work From Home Demand

COVID-19 had large impacts on demand for PCs as businesses prepared for lockdowns by purchasing notebooks to mobilise their workforce. In the second quarter of 2020, New Zealand's Traditional PC market experienced a 39.7% year-on-year (YoY) growth ... More>>


University Of Auckland: Whale-Watching By Satellite – Follow Their Travels Online

Scientists have successfully attached satellite tracking tags to six New Zealand southern right whales, or tohorā, and are inviting the public to follow the whales’ travels online. Part of a major research project involving the University of Auckland ... More>>

Commerce Commission: Kiwibank Admits System Failures And Agrees To Pay Customers $5.2 Million

Kiwibank has entered into a settlement agreement with the Commerce Commission after reporting that it failed to have in place robust home loan variation disclosure policies, procedures and systems. In a settlement dated 27 August 2020, Kiwibank admitted that ... More>>

Ministry of Health: Public Transport Distancing Requirements Relaxed

Physical distancing requirements on public transport have been reviewed by the Ministry of Health to determine whether they are still required at Alert Level 2 (or below). The Ministry’s assessment is that mandatory face covering and individuals tracking ... More>>


NZHIA: New Zealand Hemp Industry Set To Generate $2 Billion Per Annum And Create 20,000 Jobs

A new report says a fully enabled hemp industry could generate $2 billion in income for New Zealand by 2030, while also creating thousands of new jobs. Written by industry strategist Dr Nick Marsh, the report has prompted calls from the New Zealand Hemp ... More>>


Stats NZ: One In 14 Employed People Report High Risk Of Losing Jobs

About one in 14 workers say they expect to lose their job or business by mid-2021, Stats NZ said today. A survey of employed people in the June 2020 quarter showed 7 percent felt there was a high or almost certain chance of losing their job or business ... More>>

ASB Quarterly Economic Forecast: NZ Economy Doing Better Than Expected, But Challenges Remain

August lockdown estimated to have shaved 8% off NZ’s weekly GDP, and 0.5% off annual GDP Economy now expected to shrink 5% (year-on-year) by end of 2020 Unemployment rate now expected to peak at 7.2% The latest ASB Quarterly Economic Forecast is less ... More>>